Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jan. 03, 2015		Dec. 28, 2013		Dec. 29, 2012
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 68,311		$ 108,967		$ 130,770
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	269,517		98,787		85,371
Deferred income taxes	(21,216)		24,593		10,338
Loss/(gain) on sale of assets	(2,437)		(1,245)		1,099
Gain on insurance proceeds from insurance settlement	(1,550)		(1,981)		(4,272)
Increase/(decrease) in long-term pension liability	9,593		(9,010)		2,790
Stock-based compensation expense	20,807		9,433		8,904
Write-off deferred loan costs	4,330		0		725
Deferred loan cost amortization	9,949		3,451		3,042
Equity in net (income)/loss of unconsolidated subsidiary	(65,609)		(7,660)		2,662
Unrealized gain on foreign currency hedge	0		(27,516)		0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	982		4,424		(2,324)
Income taxes refundable	(22,451)		(15,316)		17,845
Inventories and prepaid expenses	(11,194)		2,059		(15,168)
Accounts payable and accrued expenses	(31,223)		8,521		3,923
Other	47,363		13,214		3,832
Net cash provided by operating activities	275,172		210,721		249,537
Cash flows from investing activities:
Capital expenditures	(228,918)	[1]	(118,307)	[1]	(115,413)	[1]
Acquisitions, net of cash acquired	(2,094,400)		(734,075)		(3,000)
Investment in unconsolidated subsidiary	0		(44,959)		(43,424)
Gross proceeds from sale of property, plant and equipment and other assets	9,262		2,358		3,870
Proceeds from Insurance Settlement	1,550		1,981		4,272
Payments related to routes and other intangibles	(11,288)		(2,423)		(137)
Net cash used by investing activities	(2,323,794)		(895,425)		(153,832)
Cash flows from financing activities:
Proceeds from long-term debt	1,842,184		344,704		0
Payments on long-term debt	(333,762)		(580)		(30,032)
Borrowings from revolving credit facility	170,143		293,235		0
Payments on revolving credit facility	(351,589)		(5,000)		0
Net cash overdraft financing	4,077		0		0
Deferred loan costs	(45,223)		(13,320)		0
Issuance of common stock	416		840,558		72
Minimum withholding taxes paid on stock awards	(10,026)		(3,289)		(4,084)
Excess tax benefits from stock-based compensation	2,420		1,138		2,652
Addition of noncontrolling interest	1,201		0		0
Distributions to noncontrolling interests	(4,272)		0		0
Net cash provided/(used) in financing activities	1,275,569		1,457,446		(31,392)
Effect of Exchange Rate on Cash and Cash Equivalents	10,980		(5,134)		0
Net increase/(decrease) in cash and cash equivalents	(762,073)		767,608		64,313
Cash and cash equivalents at beginning of year	870,857		103,249		38,936
Cash and cash equivalents at end of year	108,784		870,857		103,249
Supplemental disclosure of cash flow information:
Accrued capital expenditures	1,340		1,163		0
Cash paid during the period for:
Interest, net of capitalized interest	104,834		21,554		20,181
Income taxes, net of refunds	28,315		31,405		43,491
Non-Cash Financing Activities
Debt issued for service contract assets	$ 0		$ 0		$ 226

[1] Excludes the capital assets acquired as part of the acquisition of assets related to VION Acquisition and Custom Blenders acquisition in fiscal 2014 of approximately $984.2 million, the Terra Transaction and the Rothsay Acquisition in fiscal 2013 of approximately $167.0 million and the BioPur acquisition in fiscal 2012 of approximately $0.6 million